Partnering

While CellCure has not yet initiated focused licensing activities for C-Cure 709, we would indeed be delighted to discuss prospective partnering arrangements (including co-development scenarios).

We therefore welcome all inquiries regarding our unique technology and lead compound from pharmaceutical companies with a strong franchise in oncology.

Interested partner companies are kindly requested to contact:

Anders Trojel